Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human papillomavirus type 58 l1 protein virus-like particles
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Human papillomavirus type 58 L1 protein (virus-like particles) is a recombinant vaccine antigen designed to provide protection against HPV type 58, a high-risk oncogenic strain associated with cervical, anal, and oropharyngeal cancers. Developed by Merck Sharp & Dohme, these virus-like particles (VLPs) are composed of the L1 major capsid protein, which self-assembles to mimic the native viral structure without containing infectious genetic material. The VLPs are produced in a Saccharomyces cerevisiae (yeast) expression system. Upon administration, the particles trigger a potent humoral immune response, leading to the production of type-specific neutralizing antibodies that block viral entry into host cells. This component is a key constituent of the nonavalent HPV vaccine (Gardasil 9), which targets nine HPV types to provide broad protection against HPV-related malignancies and infections.
- Brand names
- Gardasil 9Gardasil9Gardasil-9
- Other names
- HPV 58 L1 VLPHPV58 L1 VLPHPV-58 L1 VLPhuman papillomavirus type 58 L1 protein (virus-like particles)Recombinant HPV type 58 L1 protein
02
Targets
T-cell receptor recognizing HPV58 L1-derived peptides presented by MHCBCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on human papillomavirus type 58 l1 protein virus-like particles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human papillomavirus type 58 l1 protein virus-like particles.